Adaptive Biotechnologies
company in Seattle, United States
ADPT Nasdaq
ISIN US00650F1093 SEC CIK 1478320 LEI 549300ZTF7OT1FW66Q96
Follow Adaptive Biotechnologies
Weekly email: filings, results
Revenue, last quarter
$83.9M
−10.7% vs same quarter last year
Net income
$2.9M
−69.9% vs same quarter last year
EPS, diluted
$0.02
−66.7% vs same quarter last year
Operating cash flow
$9.6M
+234.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $277M | −$59.5M |
| FY24 | $179M | −$159.5M |
| FY23 | $170.3M | −$225.3M |
| FY22 | $185.3M | −$200.2M |
| FY21 | $154.3M | −$207.3M |
| FY20 | $98.4M | −$146.2M |
| FY19 | $85.1M | −$68.6M |
| FY18 | $55.7M | −$46.4M |
| FY17 | $38.4M | −$42.8M |
| FY16 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 74.2% | −20.6% | −21.5% |
| FY24 | 59.7% | −90.8% | −89.1% |
| FY23 | 55.6% | −133.3% | −132.3% |
| FY22 | 68.7% | −108% | −108% |
| FY21 | 68.1% | −135.4% | −134.3% |
| FY20 | 77.1% | −155.3% | −148.6% |
| FY19 | 73.8% | −92.1% | −80.6% |
| FY18 | 64.7% | −89.4% | −83.4% |
| FY17 | 59.2% | −115.7% | −111.4% |
| FY16 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$48.9M |
| FY24 | −$98.9M |
| FY23 | −$167M |
| FY22 | −$200.3M |
| FY21 | −$254.5M |
| FY20 | −$168.5M |
| FY19 | $194.2M |
| FY18 | −$38.6M |
| FY17 | −$37.3M |
| FY16 | - |
- Adaptive Biotechnologies
- Healthcare median
Show the numbers
| Year | Adaptive Biotechnologies | Healthcare median |
|---|---|---|
| FY25 | −21.5% | −30.6% |
| FY24 | −89.1% | −47% |
| FY23 | −132.3% | −58% |
| FY22 | −108% | −80.4% |
| FY21 | −134.3% | −71.9% |
| FY20 | −148.6% | −62.2% |
| FY19 | −80.6% | −46.3% |
| FY18 | −83.4% | −49.6% |
| FY17 | −111.4% | −45.9% |
| FY16 | - | −36% |